ArticleCells2019
S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells.
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01558349 (Circulating Tumor Cells and Melanoma), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT (EPithelial ImmunoSPOT) and CellSearch Techniques
Who cites it
32 citing papers in PubMed, 40 citations in OpenAlex.
- Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers.Cancers · 2026Review
- Oncofetal chondroitin sulfate positive circulating tumor cells as prognostic biomarkers in early-stage melanoma.Scientific reports · 2026Article
- Circulating tumor cells as biomarkers in melanoma: techniques, challenges, and clinical applications.Frontiers in cell and developmental biology · 2026Review
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma.The journal of liquid biopsy · 2025Review
- Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.Cancer cell · 2025Review
- Pair-matched analysis of Circulating Melanoma Cells (CMCs) before and after Immunotherapy in Relation to other Melanoma-Specific Biomarkers.Journal of Cancer · 2025Article
- Liquid biopsy: paving a new avenue for cancer research.Cell adhesion & migration · 2024Review
- Article
- Liquid Biopsy in the Clinical Management of Cancers.International journal of molecular sciences · 2024Review
- Alarmins in cutaneous malignant melanoma: An updated overview of emerging evidence on their pathogenetic, diagnostic, prognostic, and therapeutic role.The Journal of dermatology · 2024Review
- A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance.NPJ precision oncology · 2024Article
- Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications.Cancers · 2024Review
- Review
- Article
- Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.International journal of molecular sciences · 2023Review
- Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023Review
- Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments.Molecular cancer · 2022Review
- Detection of cancer metastasis: past, present and future.Clinical & experimental metastasis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic melanoma is one of the most aggressive and drug-resistant cancers with very poor overall survival. Circulating melanoma cells (CMCs) were first described in 1991. However, there is no general consensus on the clinical utility of CMC detection, largely due to conflicting results linked to the use of heterogeneous patient populations and different detection methods. Here, we developed a new EPithelial ImmunoSPOT (EPISPOT) assay to detect viable CMCs based on their secretion of the S100 protein (S100-EPISPOT). Then, we compared the results obtained with the S100-EPISPOT assay and the CellSearch
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.